XTL Biopharmaceuticals
XTLB
5 hedge funds and large institutions have $1.1M invested in XTL Biopharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
36% more capital invested
Capital invested by funds: $804K → $1.1M (+$292K)
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
17% less funds holding
Funds holding: 6 → 5 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.62K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$778 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NC
1
Noked Capital
Tel Aviv,
Israel
| $469K | – | – | – |
|
|
NI
2
Noked Israel
Ramat Hasharon,
Israel
| $469K | – | – | – |
|
|
3
Morgan Stanley
New York
| $82K | +$3.62K | +400 | +5% |
|
4
Invesco
Atlanta,
Georgia
| $61K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $15K | -$778 | -86 | -5% |
|
|
6
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$2K | -325 | Closed |
|
XTLB Hedge Fund Activity: Q1 2019 in Review
5 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q1 2019, worth a combined $1.1M — up 36% from $804K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of XTLB and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Morgan Stanley, adding an estimated $3.62K. The largest seller was Deutsche Bank, exiting entirely with an estimated $2K sold.
- 5 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q1 2019, down from 6 in Q4 2018.
- Funds reported $1.1M of XTL Biopharmaceuticals stock for Q1 2019, up 36% quarter-over-quarter.
- 0 funds opened new XTL Biopharmaceuticals positions in Q1 2019 and 1 closed out, a net change of -1 holder.
- The largest XTL Biopharmaceuticals buyer in Q1 2019 was Morgan Stanley, an estimated $3.62K added.
- The largest XTL Biopharmaceuticals seller in Q1 2019 was Deutsche Bank, an estimated $2K sold.
Based on aggregated 13F filings for Q1 2019.